Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 212, Issue -, Pages S368-S371Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiv019
Keywords
Ebola virus; Kunjin replicon; vaccine; nonhuman primates
Categories
Funding
- National Institutes of Health [R21 AI053579]
Ask authors/readers for more resources
The current unprecedented outbreak of Ebola virus (EBOV) disease in West Africa has demonstrated the urgent need for a vaccine. Here, we describe the evaluation of an EBOV vaccine candidate based on Kunjin replicon virus-like particles (KUN VLPs) encoding EBOV glycoprotein with a D637L mutation (GP/D637L) in nonhuman primates. Four African green monkeys (Cercopithecus aethiops) were injected subcutaneously with a dose of 10(9) KUN VLPs per animal twice with an interval of 4 weeks, and animals were challenged 3 weeks later intramuscularly with 600 plaque-forming units of Zaire EBOV. Three animals were completely protected against EBOV challenge, while one vaccinated animal and the control animal died from infection. We suggest that KUN VLPs encoding GP/D637L represent a viable EBOV vaccine candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available